medicina58巻8号

2021年07月発行

特集 ジェネラリスト・漢方—とっておきの漢方活用術 漢方の副作用を知る

偽アルドステロン症—甘草に注意

著者： 吉野鉄大¹

所属機関： ¹慶應義塾大学医学部漢方医学センター

ページ範囲：P.1252 - P.1257

Point
◎グリチルリチンそのものやその代謝産物がアルドステロン受容体に直接結合するわけではない．
◎遠位尿細管から皮質集合管局所でのコルチゾール代謝障害がアルドステロン作用を引き起こす．
◎偽アルドステロン症発症リスクは甘草高用量（2.5 g以上/日），高齢，低アルブミン血症，便秘，直接ビリルビン高値である．
◎漢方薬だからといって気軽に併用しない！

参考文献

1）Sabbadin C, Armanini D：Syndromes that mimic an excess of mineralocorticoids. High Blood Press Cardiovasc Prev 23：231-225, 2016

studies. Endocrinology 137：1123-1128, 1996

3）Náray-Fejes-Tóth A, Fejes-Tóth G：Extranuclear localization of endogenous 11beta-hydroxysteroid dehydrogenase-2 in aldosterone target cells. Endocrinology 139：2955-2959, 1998

4）Ferrari P：The role of 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension. Biochim Biophys Acta 1802：1178-1187, 2010

5）Stewart PM, et al：Mineralocorticoid activity of liquorice；11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2：821-824, 1987

6）Conn JW, et al：Licorice-induced pseudoaldosteronism. Hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity. JAMA 205：492-496, 1968

7）Akao T, et al：Intestinal bacterial hydrolysis is indispensable to absorption of 18 beta-glycyrrhetic acid after oral administration of glycyrrhizin in rats. J Pharm Pharmacol 46：135-137, 1994

8）Akao T：Purification and characterization of glycyrrhetic acid mono-glucuronide beta-D-glucuronidase in Eubacterium sp. GLH. Biol Pharm Bull 22：80-82, 1999

studies. Endocrinology 125：1046-1053, 1989

10）Kato H, et al：3-Monoglucuronyl-glycyrrhetinic acid is a major metabolite that causes licorice-induced pseudoaldosteronism. J Clin Endocrinol Metab 80：1929-1933, 1995

11）Takahashi K, et al：Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism；A multi-centre cross-sectional study. Arch Toxicol 93：3111-3119, 2019

12）Morinaga O, et al：Isolation of a novel glycyrrhizin metabolite as a causal candidate compound for pseudoaldosteronism. Sci Rep 8：15568, 2018

13）Ishiuchi K, et al：18beta-glycyrrhetyl-3-O-sulfate would be a causative agent of licorice-induced pseudoaldosteronism. Sci Rep 9：1587, 2019

14）Sadakane C, et al：Pharmacokinetic profiles of active components after oral administration of a kampo medicine, Shakuyakukanzoto, to healthy adult Japanese volunteers. J Pharm Sci 104：3952-3959, 2015

15）Homma M, et al：Effects of long term administration of Shakuyaku-kanzo-To and Shosaiko-To on serum potassium levels. Yakugaku Zasshi 126：973-978, 2006

16）Henschkowski J, et al：Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2（11beta-HSD2）activity in hypertensive patients. Am J Hypertens 21：644-649, 2008

17）Inada M, et al：Spironolactone effective hypertension in the elderly due to 11beta-hydroxysteroid dehydrogenase type 2（11beta-HSD2）impairment；Contributory role of determining serum cortisol/cortisone ratio as a marker of 11beta-HSD2 activity. Intern Med 47：2157-2164, 2008

18）Edelman ER, et al：Case 30-2020；A 54-year-old man with sudden cardiac arrest. N Engl J Med 383：1263-1275, 2020

19）Yoshino T, et al：Risk factors for pseudoaldosteronism with rhabdomyolysis caused by consumption of drugs containing licorice and differences between incidence of these conditions in Japan and other countries；Case report and literature review. Journal of Alternaative and Complementaly Medicine 20：516-520, 2014

20）Ploeger B, et al：A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Pharm Res 17：1516-1525, 2000

21）Shimada S, et al：Liquorice-induced hypokalaemia in patients treated with Yokukansan preparations；Identification of the risk factors in a retrospective cohort study. BMJ Open 7：e014218, 2017

22）Komatsu A, et al：Risk factors associated with pseudoaldosteronism in patients with chronic hepatitis；A retrospective cohort study. Basic Clin Pharmacol Toxicol 124：607-614, 2018.

23）Yoshino T, et al：Elevated direct bilirubin - possible predictors for pseudoaldosteronism；A case-control study. Traditional and Kampo Medicine 3：174-176, 2016

24）Makino T, et al：Down-regulation of a hepatic transporter multidrug resistance-associated protein 2 is involved in alteration of pharmacokinetics of glycyrrhizin and its metabolites in a rat model of chronic liver injury. Drug Metab Dispos 36：1438-43, 2008

25）Ploeger B, et al：A population physiologically based pharmacokinetic/pharmacodynamic model for the inhibition of 11-beta-hydroxysteroid dehydrogenase activity by glycyrrhetic acid. Toxicol Appl Pharmacol 170：46-55, 2001